Skip To The Main Content

Browse these ideas available for licensing that have the potential to improve lives while creating jobs to support and grow the region.


All ideas
are listed as non-confidential technical summaries.

Ideas were generated by academic institutions, entrepreneurs, and corporations.

Ideas from our research institution partners can be reviewed by following the web links to their database.

Highlighted ideas from our partners are featured separately and organized by category. All listings are updated as new technology opportunities become available..

For assistance in connecting with, or attaining further information on any of these technologies, please contact us.

Vaccine to Protect Against Infections by Salmonella

Researchers have developed an invention to protect against Salmonella-type pathogens and more particularly, compositions and methods for immunizing against infection by typhoidal and non-typhoidal Salmonella serovars.

The invention is the creation of a fusion protein that is broadly protective across all Salmonella and is required for infection by Salmonella. Methods of immunization comprise the use of the antigenic molecules. The vaccine comprises a therapeutically effective amount of the fusion protein, comprising at least one fusion protein from Salmonella pathogenicity island 1 (SPI-1) and/or Salmonella pathogenicity island 2 (SPI-2) or variants thereof.

People and animals get sick and may die after being infected with the gastrointestinal pathogen Salmonella. Salmonella causes a wide range of human and animal diseases from typhoid to diarrhea. Currently there are no vaccines for Salmonella typhimurium and such serovars. S. enterica serotype Typhimurium and numerous other serotypes are known as the non-typhoidal Salmonella (NTS) causing salmonellosis, a severe gastroenteritis in healthy individuals, and scours in young livestock and a carrier state in older animals and poultry. Better than treatment, is prevention, and the best prevention against infectious diseases remains vaccination conferring protection and eliminating the need for antibiotics to treat these infections. The vaccine in this invention is vastly different from what is available on the market today. Proof-of-concept in mice has been completed demonstrating that the vaccine elicited an immune response that provided significant protection to the mice against a Salmonella challenge by two unique serotypes.

APPLICATIONS:
Prevention of Salmonella diseases

BENEFITS:
Broadly protective against all species for Salmonella

WHY IS IT BETTER?
The vaccine product when commercialized, will offer protection against all 2500 serovars. This vaccine is not based on Lipopolysaccharide (LPS) protection but are broadly protective based on the requirements of proteins for infection.

OTHER APPLICATIONS:
Vaccines against many Gram negative bacterial pathogens.

Additional Details

Owner

University of Kansas

Intellectual Property Protection

Unknown



Interested? Request More Information